Thanks for coming. See you next year.
Back to top
Conference News

Encouraging drug-resistant TB treatment results

26 Oct 2018

A study, led by TB Alliance, has found 89 percent of participants on the trial have been cured of drug-resistant tuberculosis (TB) after six months of treatment and six months of post-treatment follow-up through a simplified, shortened all oral regimen.

The interim results from Nix-TB, an ongoing open label study carried out at three South African sites, analyse the outcomes of orally given bedaquiline, pretomanid and linezolid over six months for extensively drug-resistant (XDR-TB) or multidrug-resistant TB (MDR-TB).

Interim results of this all oral regimen for drug-resistant TB, which cover the first 75 patients who were enrolled for six months of treatment and an additional six months of follow-up, continue to be promising in terms of both efficacy and safety.

Of the 75 participants 68 percent had XDR-TB. Francesca Conradie, University of Witwatersrand, said: “This is an encouraging way forward for patients with complicated DR-TB.

“Previously reported rate of success has been surpassed by the first 75 patients who completed six months post-treatment follow up.”

Participants who complete treatment are being followed up with for 24 months after treatment ends.

The study will be completed towards the end of 2019.


Follow Us

RT @MSF_Ind: 📢 We are at #UnionConf 'We condemn @JNJCares @JNJGlobalHealth high pricing on bedaquiline We condemn the patent extension tha…

RT @MSF_access: “We are not cases and we are not burdens and we are more than just patients. We are people. We have a right to life.” @na

RT @UnionConference: Thanks for sharing this fantastic feedback @idlidosa2 👏👏Our wonderful volunteers play a huge role in the success of #U

Receive Conference News & Updates